Bionomics Investor Presentation Deck
CAPS-5 total severity score
50
MDMA-assisted therapy significantly reduced CAPS-V scores in PTSD patients
(primary endpoint) ¹, (n=90)
40
20
10
MOU for BNC210 and MDMA Derivative (EMP-01) for Post-Traumatic Stress Disorder
Joint Feasibility Assessment
EMP-01 (3,4-Methylenedioxymethamphetamine)
0
MDMA-assisted
therapy
Placebo with
therapy
Baseline (T1)
EmpathBio O
Bionomics
After session 1
(T2)
ATAI
LIFE
SCIENCES
After session 2
(T3)
After session 3 (T4),
primary endpoint
(MDMA) derivative
✓ BNC210 + EMP-01 relieves the burden of pairing MDMA with CBT,
potentially reducing the number of CBT sessions needed with MDMA
treatment
MOU with EmpathBio's MDMA Derivative (EMP-01)
✓ Initial collaborative framework of preclinical studies to collectively
explore a combination drug treatment regimen with BNC210 and
EMP-01
MDMA-assisted psychotherapy has demonstrated significant
symptom improvement in PTSD patients
✓
FDA has granted a Breakthrough Therapy designation to MDMA-
assisted psychotherapy
✓
EmpathBio is developing MDMA derivatives that may permit the
entactogenic effects of MDMA to be separated from some of the
known adverse effects
✓ To explore the possibility of a combination treatment regimen
warranting clinical evaluation
Note: Change in CAPS-V total severity score from T1 to T4 (P < 0.0001, d = 0.91, n = 89 (MDMA n = 46)), as a measure of the primary outcome.
Primary analysis was completed using least square means from a mixed model repeated measure (MMRM) analysis model; (n=90)
1. Mitchell et al., "MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study" (2021)
13View entire presentation